Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register

References

• Cancercentrum.se [Internet]. Sweden: Cancercentrum; 2017. [cited 2017 Sep 24]. Available from: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/.
   Google Scholar
• Morigi C. Highlights from the 15th St Gallen international breast cancer conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancer. 2017;11:732.
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618.
   PubMed Web of Science ®Google Scholar
• Ma CX, Reinert T, Chmielewska I, et al. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15:261–275.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31:2013:5.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–219.
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–1846.
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757.
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–947.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Weaver KE, Camacho F, Hwang W, et al. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low income women. Am J Clin Oncol. 2013;36:181.
   PubMed Web of Science ®Google Scholar
• Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer. 2011;104:1558–1563.
   PubMed Web of Science ®Google Scholar
• Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133:367–373.
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51:S11–S21.
   PubMed Web of Science ®Google Scholar
• Cancercentrum.se [Internet]. Sweden: Cancercentrum. 2016. [cited 2016 Oct 02]. Available from: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/dokument/.
   Google Scholar
• Socialstyrelsen.se [Internet]. Sweden: Socialstyrelsen; 2016. [cited 2016 Oct 02]. Available from: https://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret.
   Google Scholar
• Makubate B, Donnan P, Dewar J, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108:1515–1524.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–537.
   PubMed Web of Science ®Google Scholar
• Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. JCO. 2009;27:3445–3451.
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–562.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. JCO. 2003;21:602–606.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. JCO. 2010;28:4120–4128.
   PubMed Web of Science ®Google Scholar
• Font R, Espinas JA, Gil-Gil M, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. 2012;107:1249–1256.
   PubMed Web of Science ®Google Scholar
• Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189–1197.
   PubMed Web of Science ®Google Scholar
• Ekholm M, Bendahl P-O, Fernö M, et al. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (>25 years) of the Phase III SBII: 2pre Trial. JCO. 2016;34:2232–2238.
   PubMed Web of Science ®Google Scholar
• Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy: results of a linguistic study focusing on patient adherence/persistence. J Support Oncol. 2007;5:139–143.
   PubMedGoogle Scholar
• Riley GF, Warren JL, Harlan LC, et al. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. MMRR. 2011;1:001–004.
   Google Scholar